15 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Leveraging Structure-Based Drug Design to Identify Next-Generation MAT2A Inhibitors, Including Brain-Penetrant and Peripherally Efficacious Leads.
Agios Pharmaceuticals
Discovery of AG-270, a First-in-Class Oral MAT2A Inhibitor for the Treatment of Tumors with Homozygous
Agios Pharmaceuticals
Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma.
Agios Pharmaceuticals
Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers.
Agios Pharmaceuticals
Amino, amido and heterocyclic compounds as modulators of RAGE activity and uses thereof
The State University of New York
Compositions and methods for treating toxoplasmosis, cryptosporidiosis and other apicomplexan protozoan related diseases
University of Washington
Cardiac glycoside analogs and their use in methods for inhibition of viral infection
The John Hopkins University
Serendipitous discovery of light-induced (In Situ) formation of an Azo-bridged dimeric sulfonated naphthol as a potent PTP1B inhibitor.
Concordia University of Wisconsin
Substituted pyrazolo[1,5-a]pyrazines as mGluR5 receptor modulators
Vanderbilt University
Hypophosphorous acid derivatives having antihyperalgic activity and biological applications thereof
Universite Paris Descartes